Objectives: Interleukin 28B (IL28B) genetic variation has been recently reported as a potent predictor of hepatitis C virus (HCV) response to interferon (IFN) therapy. The aim of this study was to produce recombinant human IL28B (rhIL28B) in yeast and explore the action mechanisms of rhIL28B as a novel anti-HCV agent.
Introduction
Since its discovery in 1957, the nature and mode of action of interferon (IFN) has been extensively studied, and these studies have indicated its importance in clinically controlling viral infections and cancers. Hepatitis C virus (HCV) is a human pathogen that infects an estimated 2.35% of the population worldwide, which is approximately 170 million individuals. 1 Chronic HCV infection is frequently associated with the development of liver cirrhosis and hepatocellular carcinoma. 1 Successful treatment of chronic HCV can greatly decrease the risk of cirrhosis and liver cancer.
Standard therapy for treatment of chronic HCV involves the subcutaneous injection of pegylated type I IFN (PEG-IFN) in combination with ribavirin oral treatment. 2 This treatment eradicates HCV infection in only 40% -50% of patients infected with genotypes 1 or 4 and 75% -90% of those infected with genotypes 2 or 3. 3 However, adverse effects due to this treatment regimen frequently lead to poor tolerance. Therefore, novel and alternative treatments that are effective and tolerated are urgently needed.
Recent genome-wide association studies have reported that human genetic variants within or near the interleukin 28B gene (il28b) are significantly associated with differing outcomes of treatment with IFN/ribavirin therapy for chronic HCV infection. 4 -7 This observation suggests the predictive and therapeutic value of interleukin 28B (IL28B) for chronic HCV. IL29, IL28A and IL28B (also known as IFN-l1, 2, and 3, respectively) belong to the type III IFN family, which is classified within the class II cytokine family. 8 IFN-ls signal through a heterodimeric receptor that comprises a long IL28 receptor a chain (IL28R1) and a short IL10 receptor b chain (IL10R2). 9 Although the short chain is ubiquitously expressed, the long chain is unique to IL28B and has a limited tissue distribution. 10 The intracellular signalling after IFN-ls receptor ligation is similar to type I IFNs and results in the phosphorylation of signal transducer and activates transcription of STAT1 and STAT2. The phosphorylated STAT1 and STAT2, together with IFN regulatory factor 9 (IRF-9), form the IFNstimulated gene factor 3 (ISGF3), which leads to the up-regulation of IFN-stimulated genes (ISGs), and finally activates multiple innate cellular defence mechanisms against viral infection.
2, 8, 11, 12 Due to their restricted receptor distribution and distinct functional mechanisms, IFN-ls may be promising candidates for clinical applications. To date, several groups have generated recombinant IL29 and have shown satisfactory in vivo antiviral activity of IL29 in a murine model and in humans. 9,11,13 -16 However, efficient protein production and biological characterization of human IL28B remain largely unknown, and understanding these functions will aid in elucidating the significance of genetic variations in the il28b gene on hepatitis C treatment.
In this study we established a simple and efficient protocol for expressing and purifying recombinant human IL28B (rhIL28B) in Pichia pastoris with potent in vitro anti-HCV activity. Cell membrane receptors, intracellular pathways and ISGs regulated by rhIL28B were also elucidated. Importantly, compared with IFN-a, rhIL28B exhibited a more specific cell-type response in terms of ISG induction.
Materials and methods

Yeast strains, cells and reagents
The PichiaPink TM Secreted Protein Expression Kit and culture media were purchased from Invitrogen (Carlsbad, CA, USA), including four protease-deleted Pichia strains and the pPINK-HC vector. The human hepatoma cell line Huh7.5.1 was provided by Dr Francis V. Chisari (Scripps Research Institute, La Jolla, CA, USA) and Huh7 was from Apath, Inc. The HepG2, Caco-2, HeLa, HEK293T, A549, DU145, K562, MCF7 and U251 cells were obtained from ATCC. The HCV genotype 1b replicon-containing cell line (2 2 3 + ) was provided by Dr Stanley Lemon (University of Texas Medical Branch, Galveston, TX, USA). The Huh7.5.1, 2 2 3 + , Huh7, HepG2, Caco-2, HeLa, MCF7 and HEK293T cells were cultured in Dulbecco's modified Eagle's medium (Gibco/Invitrogen, Carlsbad, CA, USA), the A549 cells were cultured in Fischer's -12 media (Gibco), the K562 and DU145 cells were cultured in Roswell Park Memorial Institute-1640 media (Gibco) and the U251 cells were cultured in Eagle's minimal essential medium (EMEM) (Gibco). All cell cultures were supplemented with 10% fetal bovine serum (Gibco), 1% nonessential amino acids (Gibco), 1% penicillin (Sigma, St Louis, MO, USA) and 1% streptomycin (Biofuture, Beijing, China) at 378C under 5% CO 2 .
SP-Sepharose Fast Flow was purchased from GE Healthcare (Piscataway, NJ, USA). T4 DNA ligase and all restriction enzymes were purchased from New England Biolabs (Ipswich, MA, USA). PEG-IFNa2b was from Schering Plough (Kenilworth, NJ, USA) and ribavirin was obtained from the Beijing YouAn Hospital. Commercial IL28B recombinant protein was purchased from R&D Systems (Minneapolis, MN, USA). Antibodies were obtained from Abcam (STAT1, MX1 and ISG15), Cell Signaling Technology (phospho-STAT1-Tyr701), Thermo Scientific (HCV Core) and Sigma (b-actin). Horseradish peroxidase (HRP)-conjugated secondary antibodies were from Jackson ImmunoResearch (West Grove, PA, USA).
Expression and purification of rhIL28B in P. pastoris
The human IL28B cDNA sequence (GenBank accession number NM_172139) was optimized using the Pichia codon bias (Figure 1a ) and synthesized by Genscript (Piscataway, NJ, USA). The fragment that coded for residues 18 -196 was inserted into the yeast expression vector pPinka-HC between the StuI and KpnI sites. The resulting plasmid, pPinkaHC-opt-hIL28B, was verified by DNA sequencing.
pPinkaHC-opt-hIL28B was linearized with SpeI and introduced into PichiaPink expression strains by electroporation using a Micropulser (Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions. The blank plasmid pPinka-HC was also transformed, and served as a negative control. After electroporation, 1 mL of ice-cold YPDS media was immediately added, and the cuvette contents were incubated at 308C for a minimum of 2 h without shaking. The mixture was spread onto Pichia adenine dropout (PAD) selection plates and cultured at 308C for 3 -10 days until distinct colonies were formed. White monoclonal transformants were selected from the plates and re-streaked on fresh PAD selection plates. Small-scale expression testing was performed according to the manual for screening high-level expression colonies. To achieve high levels of expression of secreted rhIL28B, the methanol concentration and induction time were evaluated in the expression procedure. The supernatant from the culture media was sampled at different final concentrations of methanol (1%, 2%, 3% and 4%, volume fraction) and induction times (36 h, 48 h, 60 h and 72 h) and was analysed for the expression of rhIL28B by SDS-PAGE.
SP-Sepharose ion exchange chromatography was used to purify the secreted rhIL28B. Under the optimal expression conditions, the supernatant from the culture media was harvested by centrifugation and applied to a column that contained SP-Sepharose Fast Flow resin preequilibrated with Buffer A (50 mM HEPES, pH 7.0). The resin was incipiently washed out with Buffer A and eluted with Buffer B (50 mM HEPES, 0.3 M NaCl, pH 7.0). The samples were analysed by SDS-PAGE and MALDI-TOF mass spectrometry and were freeze-dried for subsequent antiviral assays.
Cell culture-derived HCV (HCVcc) and the antiviral assay
The generation of firefly luciferase HCV reporter viruses (Jc1-Luc HCVcc) has been previously described. 17 Briefly, linearized pFK-Luc-Jc1 plasmid with a T7 promoter was transfected into naive Huh7.5.1 cells with Lipofectimin LTX (Invitrogen) and was followed by infection with a vaccinia virus (VV), which encoded the T7 RNA polymerase, 8 h post-transfection. Culture supernatants that were 48-72 h post-transfection were collected and filtered through 0.1 mm filters (Millipore, Billerica, MA, USA) two times to remove the VV and obtain Jc1-luc HCVcc. For the antiviral assay, Huh7.5.1 cells infected with Jc1-luc HCVcc or 2 2 3 + replicon cells were treated with various concentrations of PEG-IFNa2b, ribavirin, rhIL28B or rhIL28B plus ribavirin. The antiviral effects were evaluated by measuring luciferase activity (Promega, Madison, WI, USA) or HCV RNA abundance.
Quantitative real-time PCR (qRT-PCR)
Quantifications of HCV RNA in 2 2 3 + cells and OAS1 mRNA in HEK293 and HeLa cells were performed by qRT-PCR as previously described. 18 Briefly, total intracellular RNA was isolated using Trizol reagent (Invitrogen) according to the manufacturer's protocol. The highly conservative 5 ′ -UTR in the HCV genome was measured with the primer pair 5 ′ -GTCTAGCCATGGCGTTAGTA-3 ′ and 5 ′ -CTCCCGGGGCACTCGCAAGC-3 ′ , which were designed with AB PRISM Primer Express 2.0 software. The primer pair 5 ′ -AGAAGGCAGCTCACGAAAC-3 ′ and 5 ′ -CCACCACCCAAGTTT CCTG-3 ′ was used to quantify the OAS1 mRNA, as previously described. 19 The primer pair 5 ′ -CCAACCGCGAGAAGATGA-3 ′ and 5 ′ -CCAGAGGCGT ACAGGGATAG-3 ′ was used to quantify the b-actin mRNA, which was used as the endogenous control. All of real-time quantifications were employed using SYBR Green PCR Master Mix (ABI) on an ABI Prism 7500 System.
Receptor blocking assay
Serially diluted antibodies against hIL28BR1 or hIL10R2 (R&D Systems) were pre-incubated with the HCVcc-infected Huh7.5.1 cells at 378C for 
h prior to rhIL28B (2×10
23 mg/L) treatment and were removed by washing. A parallel IgG isotype treatment was used as a control. The cells were further cultured for 2 days in the presence of rhIL28B before the luminescence was measured.
Western blot analyses
For cell lysate preparation, monolayer cells on plates were lysed with lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40, 50 mM NaF, 1 mM Na 3 VO 4 , 5 mM b-glycerophosphate, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride). The lysate was clarified by centrifuging at 14 000×g for 20 min. Samples were mixed with 2× SDS loading buffer, boiled, and loaded onto a 10%-12% polyacrylamide gel. After electrophoresis, the proteins were transferred onto a polyvinylidene difluoride membrane (PALL, East Hills, NY, USA). The resulting blots were blocked with 5% BSA for phosphoprotein antibodies or 10% skim milk for non-phosphoprotein antibodies for 1 h and incubated with the selected primary antibody overnight at 48C. The secondary antibody used in the immunoblot was a 1 :2000 or 1: 5000 dilution of HRP-linked anti-IgG. ECL reagent (Amersham Biosciences, England, UK) was used as the substrate for detection, and the membrane was exposed to an x-ray film for visualization. The densitometries of the bands were quantified using the NIH image software and were normalized to the density of the control band.
Statistical analyses
Data analyses were performed using the t-test for two independent samples. P-values ,0.05 were considered statistically significant. All experiments were performed in triplicate, and the values are presented as the mean+SD.
Results
Expression and purification of rhIL28B in P. pastoris P. pastoris is extensively used in the production of recombinant proteins because of the high cell density in culture, lack of endotoxins, appropriate post-translational modifications and direct secretion of the product into the mineral-salt media. To obtain a high level of expression, the coding sequence of human IL28B was optimized based on the Pichia codon bias (Figure 1a) . The synthesized cDNA coding for residues 18 -196 from full-length IL28B was inserted into the pPinka-HC plasmid, and the recombinant plasmid was transformed into electrocompetent PichiaPink yeast cells. More than 110 white colonies were screened by SDS-PAGE for the expression levels of rhIL28B, and the clone with the highest level of expression was selected for further optimization of induction time and methanol concentration. As shown in Figure 1(b) , the supernatant from the PichiaPink IL28B strain induced by 3% methanol at 60 h post-induction presented the highest level of expression (196 mg/L) of the recombinant protein by the shaken bottle method.
By taking advantage of the secretion phenotype, the culture supernatants containing rhIL28B were purified by ion exchange chromatography in one step using SP-Sepharose. The eluted protein peak was present at a 0.3 M NaCl concentration. As shown in Figure 2 (a), purified rhIL28B was visible as a single band at approximately 20 kDa, with a purity .95%. The resulting protein product was subjected to identification by MALDI-TOF MS (Figure 2b ). Twelve unique peptides at different locations in the protein were observed and covered 45% of the entire protein (Figure 2c ).
Recombinant human IL28B demonstrates potent anti-HCV activity in vitro
To evaluate the antiviral activity of yeast-expressed rhIL28B, the Jc1-luc HCVcc system and Huh7.5.1 cells were used to determine the 50% cell culture inhibitory concentration (IC 50 ). As shown in Figure 3 (a), rhIL28B inhibited HCVcc infection in a dosedependent manner with an IC 50 of 0.15×10 23 mg/L, which is much lower than the IC 50 of commercial IL28B Recombinant human IL28B inhibits HCV infection Figure 3b ). In contrast, almost no cytotoxic effects from rhIL28B were detected in Huh7.5.1, HepG2 and K562 cells even when treated with 1 mg/L rhIL28B for 24 h (.6000-fold higher than the IC 50 concentration, data not shown). In addition to the 2a subgenotype HCVcc system, rhIL28B also demonstrated inhibitory effects on an HCV 1b subgenotype replicon by suppressing intracellular viral RNA replication (Figure 4a ). In 2 2 3 + replicon cells, a significant correlation was observed between the down-regulated HCV core protein and up-regulated expression of the ISG protein MX1 with an increasing concentration of rhIL28B (Figure 4b ).
In the clinical treatment of chronic HCV, ribavirin is used to enhance the antiviral action of type I IFNs. To assess a possible synergistic effect between ribavirin and rhIL28B, Jc1-luc HCVcc-infected Huh7.5.1 cells were treated with rhIL28B (0.4×10 23 mg/L) and ribavirin (25 mg/L) separately and in combination. As shown in Figure 5 , combining the two drugs resulted in a significant additive effect on HCV inhibition. Taken together, these results indicate that the yeast-produced rhIL28B has an antiviral function on HCV in vitro.
Recombinant human IL28B activates the JAK-STAT pathway and induces classical ISGs
Type I IFNs accomplish their antiviral action through activation of the Janus activated kinase-signal transducer and activator of transcription (JAK-STAT) signal transduction pathway. 2 Zhang et al. 19 previously reported the activation of JAK-STAT signalling Figure 3 . Recombinant human IL28B demonstrates antiviral activity against HCVcc. Huh7.5.1 cells were infected with Jc1-luc HCVcc 1 day before treatment and were followed by various concentrations of yeast-expressed rhIL28B (a) or commercial IL28B (b) treatment for 2 days. HCV production was measured using the luciferase assay. Cheng et al.
by a commercial IL28B that was generated in mammalian cells. Here, we analysed the intracellular signalling pathways and potential ISGs regulated by yeast-produced rhIL28B in HepG2 cells. Compared with the negative control, the phosphorylation of STAT1 occurred within 1 h upon rhIL28B stimulation, even though the basal level of STAT1 total protein was low at this timepoint ( Figure 6 ). Furthermore, the significant up-regulation of typical ISGs (MX1, STAT1 and ISG15) by rhIL28B was also detected at 24 h post-treatment ( Figure 6 ). These data suggest that rhIL28B, a type III IFN, likely exerts its biological function using a similar mechanism to type I IFNs.
Receptors IL10R2 and IL28R1 mediate rhIL28B signalling
To investigate cell membrane receptor usage by yeast-expressed rhIL28B, we performed a receptor blocking assay. Neutralizing antibodies against IL10R2 or IL28R1 were pre-incubated with Jc1-luc HCVcc-infected Huh7.5.1 cells, and the cells were treated with rhIL28B. As shown in Figure 7(a and b) , the anti-HCV capability of rhIL28B was gradually reduced with an increasing concentration of the blocking antibody, whereas the control isotype IgG failed to block the anti-HCV effect of rhIL28B. These results demonstrate that the yeast-produced rhIL28B inhibits HCV replication in an IL10R2-and IL28R1-dependent manner, which is consistent with previous reports. 9, 19 Recombinant human IL28B functions in restricted cell types
Receptor distribution and cellular responsiveness reflect the specificity and potency of therapeutic cytokines. Using MX1 Ribavirin and rhIL28B show a synergistic effect on HCV inhibition. Huh7.5.1 cells were challenged with Jc1-luc HCVcc (moi¼0.1) 1 day before the indicated treatments. The cells were further cultured for 2 days in the presence of drugs, and the luciferase assay was used to measure HCV propagation. Two sample-independent t-tests were performed between the two treatments to calculate the P value. Recombinant human IL28B inhibits HCV infection stimulation as the readout, we compared cell responsiveness to rhIL28B and IFN-a2b in multiple human cells, including hepatoma (HepG2 and Huh7), lung adenocarcinoma (A549), colorectal adenocarcinoma (Caco-2), embryonic kidney (HEK293), prostate cancer (DU145), cervical cancer (HeLa), erythromyeloblastoid leukaemia (K562), breast cancer (MCF7) and glioblastoma (U251) cells. Two cytokines demonstrated distinct ISG stimulation patterns in these cells (Figure 8a ). IFN-a2b induced MX1 expression in nearly all tested cell types, except for HEK293, at 1×10 23 mg/L. However, rhIL28B showed comparable activity to IFN-a2b only in Huh7 and DU145 cells. A549, HepG2 and Caco-2 cells showed responsiveness to relatively high concentrations of rhIL28B (1×10 22 mg/L). To further verify this result, the induction of another classical ISG, OAS1, was measured by qRT -PCR in MX1 low-expression cells HEK293 (Figure 8b ) and HeLa (Figure 8c ). The restricted cell responsiveness to rhIL28B may contribute to tissue-targeted therapy in the liver, prostate and lung. This type of selectivity also suggests the presence of decreased side effects during HCV treatment.
Discussion
As the major component of the current standard therapy for chronic HCV infection, IFN-a often causes several adverse events, including influenza-like symptoms, depression, and haematologic events such as anaemia and neutropenia. 20 More secure and specific agents for treating HCV with fewer adverse effects than IFN-a would be very beneficial. The discovery of the association between IL28B genotypes and the clinical outcome of IFN-a treatment on HCV suggests a possible involvement of IL28B in the pathogenesis and control of HCV infection. 4 -7 Therefore, for the systematic study of the biological function of IL28B, we developed a simple and efficient protocol for the scalable production of rhIL28B in a P. pastoris expression system with potent in vitro anti-HCV activity, which is significantly better than the commercial CHO cell-derived recombinant protein. This may be partially caused by the following reasons.
In this study, the yeast-produced rhIL28B contains the residues 18 -196 from full-length IL28B and no extra amino acid, whereas the commercial CHO-derived recombinant protein is composed of residues 30-200 with a 6-histidine tag fused at the C terminus. In addition, the secretion expression and the relatively simple and time-saving purification procedure may contribute to the superior activity of yeast-produced rhIL28B. Furthermore, as a possible therapeutic candidate, rhIL28B produced in the current system is advantageous because of the ease of methanol induction, secretion, and purification.
In addition to the generation of rhIL28B, a systematic characterization of the recombinant protein was also performed to evaluate its biological activity and to determine the mechanism of action. It is known that IL28B induces the JAK-STAT pathway by binding to the IL28R1 and IL10R2 receptor complex, which in turn leads to activation of intracellular signalling pathways and up-regulation of ISGs, similar to IFN-a. 2, 9, 19 Our results further verified this mechanism. We showed that binding to IL28R1 or IL10R2 is necessary for the anti-HCV activity of rhIL28B. Furthermore, the phosphorylation of STAT1 occurred within 1 h upon rhIL28B stimulation, and the expression of some known ISGs was induced within 24 h. Notably, Marcello and colleagues observed that IL29 suppressed HCV replication with different kinetics and magnitude compared with IFN-a. 21 This finding suggests that type III IFNs, including IL28B, may not be a simple alternative cytokine to IFN-a through the distinct strength and duration of action. In addition, signalling pathways that are regulated by IL28B, other than the JAK-STAT pathway, need to be further elucidated.
The receptor complex of type III IFNs consists of a short IL10R2 chain that is ubiquitously expressed and a long chain IL28R1 that has a limited tissue distribution. 10 It is known that the expression of cell surface receptors is directly correlated with the stimulation of ISGs by IFNs. Here, we observed that rhIL28B had a more restricted cell-type specificity in hepatocytes, prostate cells, alveolar epithelial cells and epithelial colorectal cells, whereas nearly all of the tested cells responded to Cheng et al.
IFN-a. These results suggest a narrow distribution of IL28B receptors and highlight the tissue-targeted therapeutic potential of IL28B. In addition to the liver, IL28B may be suitable for antiviral treatment and immunoregulation in prostate, lung and colorectal cells. An expected benefit of IL28B treatment is safety, which is supported by the absence of ISG induction by IL28B in HeLa, K562, MCF7 and U251 cells. Therefore, with its potent antiviral activity in the liver and the restricted cellular responsiveness in other tissues, rhIL28B is a promising drug candidate for chronic HCV treatment. Currently a clinical trial of pegylated IL29 has demonstrated clear antiviral activity in patients with chronic infection of genotype 1 HCV and has been associated with fewer adverse events and haematologic side effects. 16 Moreover, in vitro studies have shown that IFN-a induces the expression of type III IFNs and that the anti-HCV activities of type I IFN or type III IFN are synergistic. 21, 22 Our data also provide evidence of the synergistic effect of ribavirin and rhIL28B. These findings suggest a tight connection between IFN-a and IL28B, and a treatment regimen of a combination of IFN-a, IL28B and ribavirin may be a more effective therapy for HCV treatment.
In conclusion, our study constructed a P. pastoris expression system that efficiently prepares rhIL28B and unravelled the distinct mode of action for rhIL28B in terms of antiviral activity and cell-type responsiveness. More detailed mechanistic studies on IL28B-regulated cellular events and preclinical studies of IL28B as a therapeutic agent are needed in the future.
